drugset / Trial / NCT04027530

Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.

NCT04027530

Phase 4 Completed 40 enrolled Amsterdam UMC, location VUmc
RandomizedCrossoverQuadruple-blindPrevention

Summary

Current study will render insight in to the role of renal hypoxia in the diabetic kidney and is able to associate its finding with measurements of renal perfusion and glomerular filtration rate. Moreover, this research will focus on the effects of sodium-glucose cotransporter 2 inhibition on renal tissue oxygenation and oxygen consumption as well as a change in intrarenal hemodynamics and perfusion, and a shift of fuel metabolites. Elucidation the mechanisms underlying the effects of SGLT2 inhibition will advance our knowledge and contribute to their optimal clinical utilization in the treatment of chronic kidney disease in diabetes and possibly beyond.

Timeline

Start
2020-12-10
Primary completion
2023-01-09
Completion
2023-01-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ertugliflozin Unknown 15 mg Oral